EcoDrugPlus

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSATEG00000009195
Gene Symbol: CACNA1BA
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSATEG00000001518
Gene Symbol: CACNA1AB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSATEG00000018264
Gene Symbol: CACNA2D1A
3 Cross references
230 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSATEG00000024865
Gene Symbol: CACNA2D2A
3 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSATEG00000000216
Gene Symbol: CACNB1
3 Cross references
210 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSATEG00000016851
Gene Symbol: CACNB3A
1 Cross references
203 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3b

Ensembl ID : ENSATEG00000021180
Gene Symbol: CACNB3B
2 Cross references
204 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1b

Ensembl ID : ENSATEG00000024649
Gene Symbol: CACNG1B
2 Cross references
197 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 3b

Ensembl ID : ENSATEG00000003570
Gene Symbol: CACNG3B
2 Cross references
194 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSATEG00000024647
Gene Symbol: CACNG4B
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5b

Ensembl ID : ENSATEG00000024434
Gene Symbol: CACNG5B
2 Cross references
172 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6b

Ensembl ID : ENSATEG00000022354
Gene Symbol: CACNG6B
2 Cross references
177 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).